Valiant Laboratories Ltd

Valiant Laboratories Ltd has announced the closure of its trading window for all directors, promoters, designated persons, and connected individuals. This restriction will be in effect from July 01, 2026, until 48 hours after the declaration of the financial results for the quarter ended June 30, 2026. The move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct, aimed at preventing insider trading during the sensitive period leading up to and immediately following the financial results announcement. The company has also updated its website with this information.

Valiant Laboratories Ltd received an order from the Joint Commissioner, CGST & C. Ex., Navi Mumbai, confirming a GST demand of ₹18 Lakhs related to a Corporate Guarantee, along with a penalty of ₹18 Lakhs and applicable interest. This stems from a Show Cause Notice dated January 14, 2026. Other alleged violations regarding Input Tax Credit on IPO expenses (approximately ₹2.85 Crore) and turnover mismatch for FY 2021-22 (approximately ₹9.31 Crore) were dropped. The company is evaluating options, including filing an appeal.

Valiant Organics Limited (VOL) will acquire 1,86,07,531 equity shares, representing 34.26% of the share capital, of Valiant Laboratories Limited (VLL) from Dhanvallabh Ventures LLP through an off-market transaction. The acquisition is part of a restructuring exercise by VOL and is subject to regulatory approvals. Post-transaction, Dhanvallabh Ventures LLP will hold 12.58% of VLL.

Valiant Laboratories Ltd's board has approved exploring potential restructuring options among the company, its holding, subsidiaries, and associates. The aim is to achieve operational, organizational, and strategic synergies. Restructuring may involve amalgamation, merger, demerger, transfer, or reorganization. The board will further evaluate the matter and make future decisions as appropriate, with necessary disclosures made in accordance with SEBI regulations.

Valiant Laboratories Ltd. has announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results in a meeting held on May 14, 2026, after considering the audit report issued by Raman S. Shah & Co., Chartered Accountants. The results are available on the company's website.

Valiant Laboratories Ltd's Monitoring Agency Report for the quarter ended March 31, 2026, indicates that funds raised through the Rights Issue of equity shares have been utilized appropriately for the objects mentioned in the offer document. India Ratings and Research Private Limited issued the report, which was reviewed by the Audit Committee and Board of Directors on May 14, 2026. The report confirms no deviation from the stated objectives, based on management undertaking and a Statutory Auditor Certificate.

Valiant Laboratories Ltd has appointed Ketki D Visariya & Co. as the Cost Auditors and Rajesh Chheda & Co. as the Internal Auditors for the financial year 2026-27. The appointments were approved at the Board of Directors meeting held on May 14, 2026, pursuant to the Companies Act, 2013. Both firms have been re-appointed for the FY 2026-27.

Valiant Laboratories Ltd. has announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results in a meeting held on May 14, 2026, after considering the audit report issued by Raman S. Shah & Co., Chartered Accountants. The meeting commenced at 03:30 P.M and concluded at 05:30 P.M. The results and audit report are available on the company's website.

Valiant Laboratories Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, in a meeting held on May 14, 2026. The board also took on record the audit report issued by Raman S. Shah & Co., Chartered Accountants. The meeting commenced at 03:30 P.M and concluded at 05:30 P.M. The results and audit report are available on the company's website.

Valiant Laboratories Ltd has scheduled a Board of Directors meeting on May 14, 2026, to consider and approve the standalone and consolidated audited financial results for the quarter and year ended March 31, 2026. The trading window, which closed on March 26, 2026, will remain closed until May 16, 2026, as per SEBI regulations.